Abstract 497P
Background
The primary site of colorectal cancer (CRC) influences survival outcomes when metastasized to the liver or lung, with left-sided CRC being associated with longer survival than right-sided CRC. Additionally, the timing of metastasis, whether synchronous or metachronous, has been suggested as a factor for survival, with synchronous metastasis generally considered more aggressive than metachronous CRC with brain metastasis (BM). We investigated the effect of both CRC’s primary location and metastatic timing on overall survival (OS) upon metastasis to the brain.
Methods
We systematically searched PubMed, Embase, and the Cochrane Library. We included studies that described patients diagnosed with BM from CRC, with reports on survival outcomes based on different primary tumor sites (left vs right) or metastatic timing (synchronous vs metachronous). Within the eligible studies, we extracted hazard ratios (HR) for OS and conducted a meta-analysis by using the random-effect model.
Results
Out of 5836 studies identified through our search, 7 studies met the inclusion criteria for the meta-analysis. Similar to lung and liver metastasis of CRC, left-sided primary CRC exhibits better OS than right-sided CRC (multivariate HR = 0.71, 95% CI: 0.54-0.94, univariate HR = 0.75, 95% CI: 0.57-0.99) when metastasized to the brain. Regarding the timing of metastasis, we found no significant difference in OS between synchronous and metachronous metastasis (HR = 0.83, 95% CI: 0.48-1.43). Table: 497P
Hazard ratio of the included studies
Study | HR | 95% CI | |
Right colon vs left colon (reference = right), multivariate analysis | |||
Bergen 2021 | 0.65 | 0.46-0.92 | |
Chen 2022 | 0.94 | 0.56-1.57 | |
Chen 2023 | 0.49 | 0.18-1.34 | |
Total | 0.71 | 0.54-0.94 | I2: 0% |
Right colon vs left colon (reference = right), univariate analysis | |||
Bergen 2021 | 0.63 | 0.44-0.89 | |
Bonadio 2021 | 1.14 | 0.80-1.62 | |
Chen 2022 | 0.74 | 0.48-1.14 | |
Chen 2023 | 0.37 | 0.17-0.81 | |
Michl 2015 | 0.79 | 0.57-1.09 | |
Total | 0.75 | 0.57-0.99 | I2: 58% |
Synchronous vs metachronous (reference = metachronous), univariate analysis | |||
Chen 2023 | 0.83 | 0.44-1.58 | |
Mege 2013 | 0.50 | 0.10-2.60 | |
Tanriverdi 2014 | 1.14 | 0.31-4.13 | |
Total | 0.83 | 0.48-1.43 | I2: 0% |
Abbreviations: HR, hazard ratio; CI, confidence interval
Conclusions
Left-sided colon cancer exhibited higher OS compared to right-sided colon cancer, consistent with findings in lung and liver metastasis. However, OS did not differ between synchronous and metachronous metastasis. Further studies comparing the genotypes and mutations of CRC with BM based on their primary location and metastatic timing are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16